AstraZeneca, Cellworks to target drug combos against drug-resistant TB
This article was originally published in Scrip
Executive Summary
AstraZeneca and Cellworks have agreed to collaborate, through a project funded by the Wellcome Trust, on the development of combination treatments for tuberculosis, including multidrug-resistant strains that for the most part are largely not affected by current combo treatment.